Docetaxel Injection, Solution
Product Images NDC 0409-0367

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 0409-0367). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Docetaxel 01)

Chemical structure of Docetaxel, a chemotherapy medication. The diagram shows the molecule's detailed atomic bonds and configuration, including multiple rings, hydroxyl groups, methyl groups, and ester functionalities, representing the drug's molecular composition.*

FDA Label Image

Figure 1 (Docetaxel 02)

A Kaplan-Meier curve showing disease-free survival (DFS) probability over time in months for two treatment groups labeled TAC and FAC. The graph illustrates the DFS percentage on the vertical axis and disease-free survival time (months) on the horizontal axis, comparing outcomes between the two groups during the study period up to 66 months.*

FDA Label Image

Figure 2 (Docetaxel 03)

A Kaplan-Meier (K-M) curve titled 'TAX316 Overall Survival K-M Curve' showing survival probability percentage over survival time in months. The chart compares two lines labeled TAC and FAC, depicting their respective overall survival probabilities over a time span from 0 to 66 months.*

FDA Label Image

Figure 3 (Docetaxel 04)

A Kaplan-Meier survival curve chart displaying overall survival probabilities over time in months, comparing Docetaxel 75 mg/m2 (solid line) versus Best Supportive Care (dashed line) in a survival study. The graph shows cumulative survival probability on the vertical axis and survival time (months) on the horizontal axis, with a reported log-rank p value of 0.010.*

FDA Label Image

Figure 4 (Docetaxel 05)

A Kaplan-Meier survival curve chart titled 'TAX320 Survival K-M Curves - Docetaxel 75 mg/m² vs. Vinorelbine or Ifosfamide Control.' The graph plots cumulative survival probability over survival time in months, showing two survival lines comparing Docetaxel and control treatments, with an overall survival log-rank p value of 0.13.*

FDA Label Image

Figure 5 (Docetaxel 06)

A Kaplan-Meier survival curve chart titled 'Figure 5 - TAX327 Survival K-M Curves' depicting survival probability over time in months. The graph compares two groups represented by solid and dotted lines labeled T75 q3w and M q3w, showing changes in survival probability from 1.0 to 0.0 over a 30-month period.*

FDA Label Image

Figure 6 (Docetaxel 07)

A Kaplan-Meier curve illustrating time to progression in a gastric cancer study (TAX325). The graph plots probability (%) over time (months) comparing two treatment groups, TCF and CF, showing the decline in progression-free probability over 24 months.*

FDA Label Image

Figure 7 (Docetaxel 08)

A Kaplan-Meier survival curve from a gastric cancer study (TAX325) showing survival probability percentages over time in months. The graph compares two treatment groups labeled TCF and CF, illustrating differences in survival rates between them.*

FDA Label Image

Figure 8 (Docetaxel 09)

A Kaplan-Meier (K-M) curve chart illustrating progression-free survival (PFS) probability (%) over time in months, comparing two treatment groups labeled TPF and PF. The chart shows the decline in PFS probability for both groups across a 42-month period.*

FDA Label Image

Figure 9 (Docetaxel 10)

A Kaplan-Meier curve chart titled 'Figure 9 -TAX323 Overall Survival K-M Curve' showing survival probability (%) over survival time in months. The chart compares two groups, TPF and PF, with survival probabilities plotted from 0 to 72 months on the x-axis and 0 to 100% on the y-axis.*

FDA Label Image

Figure 10 (Docetaxel 11)

Kaplan-Meier survival curve depicting overall survival probability (%) over 72 months for two treatment groups labeled TPF (n=255) and PF (n=246). The chart includes survival probability on the y-axis and survival time in months on the x-axis, along with the number of patients at risk shown for various time points below the graph.*

FDA Label Image

Logo (Docetaxel 12)

FDA Label Image

Logo (Docetaxel 12a)

FDA Label Image

Principal Display Panel (1 mL Vial Label)

Label for Docetaxel Injection, USP 20 mg/mL in a 1 mL single-dose vial. It is for intravenous use and labeled as a cytotoxic agent. The label advises discarding unused portions and checking concentration prior to preparation. Manufactured by Hospira, Inc.*

FDA Label Image

Principal Display Panel (1 mL Vial Carton)

Packaging label for Docetaxel Injection, USP 20 mg/mL intravenous solution by Hospira, Inc. The label states it is a single-dose vial (1 mL) ready to add to infusion solution, with warnings to check concentration before preparation and keep out of reach of children. It includes ingredients, storage instructions, and a caution noting it is a cytotoxic agent.*

FDA Label Image

Principal Display Panel (4 mL Vial Label)

Label for Docetaxel Injection, USP 80 mg/4 mL (20 mg/mL) multiple-dose vial. The label indicates it is sterile and for intravenous use only, labeled as Rx only. It includes dosing concentration information and cautions about preparation and use. The labeler is Hospira, Inc.*

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

Box packaging label for Docetaxel Injection, USP 80 mg/4 mL (20 mg/mL) solution for intravenous use. The label indicates the product is ready to add to infusion solution, distributed by Hospira, Inc. The box design features warnings to keep out of reach of children and instructions to check concentration prior to preparation. Storage conditions and handling cautions are also noted.*

FDA Label Image

Principal Display Panel (8 mL Vial Label)

Label for Docetaxel Injection, USP 160 mg/8 mL (20 mg/mL) multiple-dose vial. The label notes it is sterile, for intravenous use only, with a warning to check concentration prior to preparation. It lists active ingredients including docetaxel and excipients, and includes storage instructions and caution about light protection and cytotoxicity. The label shows the NDC code 0409-0368-01 and the labeler Hospira, Inc.*

FDA Label Image

Principal Display Panel (8 mL Vial Carton)

Packaging label for Docetaxel Injection, USP 160 mg/8 mL (20 mg/mL) intravenous injection solution. The label indicates a one-vial multiple-dose vial formulation, distributed by Hospira, Inc. It includes instructions to add to infusion solution and warnings about cytotoxic properties and storage conditions. The label also emphasizes checking concentration prior to preparation and keeping out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.